TICKERNERD
Menu
RPIDRPIDHealthcare · Medical Devices

RPID Stock Forecast: Rapid Micro Biosystems, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.67
0.00% on the day

The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. hold a median 12-month price target of $7 — +319.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$84.3M
Ticker Nerd rank
32 / 100
Median analyst target
$7.00
Analysts covering
4
Total return, dividends reinvested
1W
−0.6%
1M
−20.5%
YTD
−42.4%
1Y
−37.7%
From 52W high
−64.3%
From 52W low
+7.7%
$1.55
$4.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RPID stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rapid Micro Biosystems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Size
77
Revisions
66
Volatility
49
Quality
33
Growth
31
Value
29
Momentum
13
Issuance
10

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RPID stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RPID, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26RPIDHigh $8.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5.00Median $7.00High $8.00

The green dot is the last close — the median target sits +319.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026KeybancMaintainsOverweight$8.00 → $5.00
22 May 2026Lake StreetMaintainsBuy$8.00 → $7.00
28 July 2025Lake StreetInitiatesBuy—
12 Feb 2025KeybancInitiatesOverweight—
7 Mar 2023Morgan StanleyReiteratesEqual-Weight—
16 Aug 2022JP MorganDowngradeNeutral—
11 May 2022Morgan StanleyMaintainsEqual-Weight—
7 Mar 2022Morgan StanleyMaintainsEqual-Weight—
15 Feb 2022Morgan StanleyMaintainsEqual-Weight—
15 Nov 2021Morgan StanleyMaintainsEqual-Weight—
9 Aug 2021Cowen & Co.InitiatesOutperform—
9 Aug 2021JP MorganInitiatesOverweight—
9 Aug 2021Morgan StanleyInitiatesEqual-Weight—
9 Aug 2021StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RPID appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RPID analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Rapid Micro Biosystems, Inc. (RPID) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
2.4×

Cheaper than 49% of US stocks

Price / book
4.7×

Cheaper than 23% of US stocks

EV / EBITDA
−1.9×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
10.9%

Higher than 55% of US stocks

Earnings growth (YoY)
10.9%

Higher than 49% of US stocks

Gross margin
15.0%

Higher than 14% of US stocks

Operating margin
−153.0%

Higher than 12% of US stocks

Net margin
−145.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−141.6%

Higher than 10% of US stocks

Return on assets
−46.4%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RPID vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RPIDRapid Micro Biosystems, Inc.$84.3M
32
SERASera Prognostics, Inc.$83.8M
40
OMOutset Medical, Inc.$77.0M
29
LUNGPulmonx Corp.$93.2M
74
CVRXCVRx, Inc.$74.7M
34
ECORelectroCore, Inc.$94.8M
54
HYPRHyperfine, Inc.$95.7M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rapid Micro Biosystems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RPID news & analysis

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

Zacks Investment Research · 19 Aug 2026positive

Rapid Micro Biosystems (RPID) shares have fallen 25.7% over the past four weeks and are now technically in oversold territory. Wall Street analysts show strong agreement in revising earnings estimates upward, which the piece suggests could signal a trend reversal.

Why it matters — RPID watchers would care because the combination of an oversold technical reading and upward analyst estimate revisions could indicate a shift in the stock's recent downward trajectory.

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 12 Aug 2026positive

Rapid Micro Biosystems (RPID) was upgraded to a Zacks Rank #2 (Buy). The upgrade reflects growing optimism about the company's earnings prospects.

Why it matters — The upgrade signals a change in analyst sentiment toward RPID's earnings outlook that watchers of the stock may find notable.

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Rapid Micro Biosystems, Inc. (RPID) held its Q2 2026 earnings call, and the transcript of that call was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and related discussion.

Why it matters — RPID watchers can review the full Q2 2026 earnings call transcript to hear management's commentary on the company's recent performance and outlook.

Rapid Micro Biosystems Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Rapid Micro Biosystems reported second-quarter revenue of $8.1 million, an 11% increase from $7.3 million a year earlier, which exceeded the company's prior guidance. The growth was driven by higher consumable sales, service activity, and recurring revenue.

Why it matters — This beats the company's own guidance and shows growing strength in recurring revenue streams, a key signal for RPID watchers assessing commercial traction.

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Rapid Micro Biosystems reported a Q2 quarterly loss of $0.27 per share, matching its year-ago loss but slightly wider than the Zacks Consensus Estimate of a $0.26 loss. Revenue came in above analyst estimates for the quarter.

Why it matters — RPID watchers would note that the quarterly loss was slightly worse than consensus, though revenue exceeded estimates, offering a mixed read on the company's recent financial performance.

FAQ

Frequently asked questions about RPID stock

What is the RPID stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RPID stock a buy right now?

Of the 4 analysts covering Rapid Micro Biosystems, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapid Micro Biosystems, Inc. 32 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RPID?

As at 22 Aug 2026, Rapid Micro Biosystems, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

Will RPID stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +319.2% from the last close, and Ticker Nerd's factor model ranks Rapid Micro Biosystems, Inc. 32 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RPID stock forecast for 2030?

No analyst covering Rapid Micro Biosystems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has RPID stock performed over the past year?

Rapid Micro Biosystems, Inc. returned -37.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rapid Micro Biosystems, Inc. do?

Rapid Micro Biosystems, Inc. is a prominent entity in the life sciences sector, focusing on automation solutions for microbial detection in pharmaceutical manufacturing.

What is the latest news on RPID?

The most recent item we track (Zacks Investment Research, 19 Aug 2026): "Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)". Rapid Micro Biosystems (RPID) shares have fallen 25.7% over the past four weeks and are now technically in oversold territory. Wall Street analysts show strong agreement in revising earnings estimates upward, which the piece suggests could signal a trend reversal.

Company

About Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc. is a prominent entity in the life sciences sector, focusing on automation solutions for microbial detection in pharmaceutical manufacturing. The company's primary function is to enhance quality control processes through advanced technologies, enabling quicker and more reliable detection of microbial contamination. Rapid Micro Biosystems operates in an industry that demands stringent safety and regulatory compliance, thus playing a crucial role in ensuring product integrity and patient safety. Its innovative detection systems, designed to meet the needs of biopharmaceutical companies and related industries, underscore significant technological advancements in microbial quality control. As the company continues to evolve within its market, it actively contributes to improving operational efficiency and safeguarding public health through cutting-edge scientific solutions.

CEO Mr. Robert G. Spignesi Jr. · 171 employees · United States · https://www.rapidmicrobio.com